AimmuneLink, a Korean company specializing in precision immunity analysis and measurement technology, has secured seed funding from Seoul Techno Holdings. The investment amount remains undisclosed.

AimmuneLink is a precision immunity-focused enterprise providing data-driven immunity analysis and measurement services to pharmaceutical and vaccine companies as well as medical institutions. In 2024, it prepared for its launch through the Pre-Startup Package program, earning recognition for its technology and commercialization potential by winning top awards at the SNU-SH Demo Day (hosted by Seoul National University Siheung Campus) and the Seoul Hongneung Innopolis GRaND-K Startup Competition.

Sang-joon Hwang, CEO of AimmuneLink, said, “Immunity plays a critical role in daily life, linked to disease and aging. AimmuneLink aims to develop and commercialize immunity analysis and measurement tests useful not only in everyday life but also in pharmaceutical development. We are grateful to SNU Holdings for their significant investment in realizing this vision.”

With this funding, AimmuneLink plans to accelerate the development and commercialization of its immunity testing technology, expand its immunity big data, and advance machine learning to implement a personalized precision medicine platform based on Immune Digital Twins.

Seung-hwan Mok, CEO of Seoul Techno Holdings, stated, “Despite its growing importance, accurate immunity testing services remain scarce. We support AimmuneLink, with its technical expertise and commercialization experience, to address unmet market needs and grow into a global company.”

This investment stems from a Pre-Startup Package agreement between SNU Holdings and Seoul National University Siheung Campus. Moving forward, SNU Holdings intends to further develop this partnership, actively identifying and supporting promising tech-driven startups like AimmuneLink, while strengthening collaboration to energize the national advanced bio cluster led by the Siheung Campus.